QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at
Q3 2026 results:
Net sales of $548 million rise 3% and also 3% at constant exchange rates (CER)
Adjusted operating income margin of 30.4% rises 0.8 percentage points
Diluted EPS of $0.51; adjusted diluted EPS
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transaction may contain terms that could limit superior competing offers.Shareholders are encouraged to
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted
QIAGEN and EQT Private Equity agree on an all-cash public takeover offer for all outstanding QIAGEN shares at an offer price of €46.50 per share, a premium of 40.3% to the unaffected share price
Following a
Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis
QuantiFERON-TB Gold Plus detects tuberculosis (TB) infection as an
New IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the results
New QIAGEN Discovery Platform extends AI into drug discovery
Bloodstream infections can trigger sepsis, a life-threatening response to infection; about 1.7 million U.S. adults develop sepsis each year, contributing to at least 350,000 deaths
New QIAstat-Dx test identifies
Compact system offers research laboratories a time-saving and cost-efficient way to automate work still done by hand
Reduction in hands-on time of over 80% compared with manual sample processing
Third new sample
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET.
Shareholders will be asked to vote on
New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety
Builds on more than 3,300 cumulative placements of
Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall
To assume CEO role on September 1, 2026,
